Literature DB >> 29905457

Treatment Modalities and Outcomes of Infantile Hemangiomas at Srinagarind Hospital.

Leelawadee Techasatian.   

Abstract

Background: There are many treatment modalities for infantile hemangiomas. During the past decades, systemic corticosteroid was the mainstay therapy in this condition. However, the most recent option of using oral propranolol has been considered as a first line therapy instead of systemic corticosteroid. On the other hand, there are still many treatment modalities which can be used as an alternative option in treating this condition. Objective: To explore the epidemiology of infantile hemangiomas, treatment modalities and outcomes at Srinagarind Hospital during 2004-2014. Material and Method: Retrospective chart reviewed from the out patient clinic’s database at Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Thailand.
Results: There were a total of 154 infantile hemangiomas. Female to male ratio was 1.8:1. The most common locations of infantile hemangiomas were head and neck areas (69.0%), followed by extremities (21.0%) and trunk (10.0%). Treatment modalities for infantile hemangiomas during the past 10 years (based on initial approaches) were oral propranolol (57.1%), oral prednisolone (17.5%), surgery (10.4%), interferon alpha (9.8%), vincristine (4.5%) and laser (0.6%). All treatment modalities showed high efficacy in treating this condition.
Conclusion: There are many effective treatment modalities for infantile hemangiomas. Even though oral propranolol has become the first line therapy in this condition, other treatment options are still effective and useful, especially with those unresponsive to oral propranolol.

Entities:  

Mesh:

Year:  2016        PMID: 29905457

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  1 in total

1.  Propranolol vs. steroids in the treatment of infantile hemangiomas: A meta-analysis.

Authors:  Yiting You; Yadong Li; Yiting Xiao; Jinsong Zhang
Journal:  Mol Clin Oncol       Date:  2021-06-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.